Paris (France), February 26, 2026 2025 annual resultsStrong performance driving significant cash generation and deleveragingSegment revenue of $1,165m, up +4% year-on-yearGeoscience revenue up +10% to $444m, driven by all our three core basins as well as the Middle East, and Earth Data revenue up +6% to $406m, fueled by market appetite for high-end data and sector consolidationStrong improvement in profitability, supported by operating efficiency gains across all business lines. Segment adjusted EBITDAs of $551m, up +21% year-on-year, representing a 47% margin vs 41% in 2024IFRS Net Income of $71m, up +40% compared with 2024Significant Net Cash Flow generation of $107m, exceeding the FY 2025 guidance of $100mContinued reduction in Net Debt (excluding IFRS 16) to $753mFY 2026 guidance: expected Net Cash Flow generation of...

2025 Normalised PBT of €10.6 Million Exceeds Outlook Sales for 2025: €484.3m, up 9% from 2024 Sales for Q4 2025: €136.7m up 6% from Q4 2024 Net Margin for 2025: €50.7 million, up €5.5 million EBITDA for 2025 was €22.8m up from €18.0m 2024 Normalised Profit Before Tax: €10.6 million vs. €7.4 million in 2024 Net Profit: €7.4 million, improved from a €2.8 million profit in 2024 EPS for 2025: Positive €0.2313 cents per share, vs. positive €0.0866 in 2024 Total Assets: €279.4 million, up €25.5 million from the beginning of the year Equity ratio at 29.5% compared to 30% at the end of 2024 2026 Normalised PBT Outlook: €11.5 million to €13.5 million The VA S-Europe division reported sales of €60.3 million in the fourth quarter, a 1.2% decrease compared to the same period in 2024. Total sales for the year amounted...

Hagnaður yfir afkomuspá ársins.  Hagnaður fyrir skatta af reglulegri starfsemi árið 2025 var 1,5 milljarður króna Rekstrartekjur samstæðunnar námu rúmlega 70,1 milljarði ISK (€484.3m) fyrir árið 2025 sem er 9% aukning frá 2024 Rekstrartekjur á fjórða ársfjórðungi 2025 námu 19,8 milljörðum ISK: (€136.7m), sem er aukning um 6% frá sama ársfjórðungi 2024 Framlegð 2025 var 7,3 milljarðar (€50.7m) hækkar um 799 milljónir ISK milli ára (€5.5m) EBITDA fyrir árið 2025 er 3,3 milljarðar ISK (€22.8m), en var 2,6 milljarður ISK (€18.0m) á árinu 2024 Hagnaður fyrir skatta af reglulegri starfsemi er 1,5 milljarður ISK (€10.6m) samanborinn við 1,1 milljarð ISK (€7.4m) 2024 sem er aukning um 457 milljónir ISK (€3.2m) Hagnaður ársins eftir skatta er 1,1 milljarður ISK (€7.4m) samanborinn við 402 milljóna ISK hagnað (€2.8m) 2024 Hagnaður...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites in the U.S., U.K. and EU, with 15 systemic lupus erythematosus patients enrolled to date, supported by increased interest in FT819 safety, efficacy and on-demand accessibility profile Colorectal cancer patient shows greater than 50% reduction in CEA levels with tumor reduction across all target lesions after treatment with FT836, a MICA/B-targeted off-the-shelf...

Full Year Highlights – 2025 vs. 2024Verification and certification revenue: $20.1M vs. $20.6MProduct sales: $3.6M vs. $3.8MTotal revenue: $24.9M vs. $25.7MNet income: $1.5M vs. $2.1MDiluted EPS: $0.30 vs. $0.40Cash generated from operations: $1.6M vs. $2.7MCash & cash equivalents: $3.2M vs. $2.0M at 2024 year-endStock buybacks: 183,016 sharesTotal buybacks since plan inception (including private purchases): 1,374,652 shares at purchase price of approximately $15.2 millionFourth Quarter Highlights – 2025 vs. 2024Verification and certification revenue: $5.0M vs. $5.4MProduct sales: $0.7M vs. $0.9MTotal revenue: $6.0M vs. $6.7MNet loss of $0.2M vs. net income of $1.0MDiluted EPS: ($0.04) vs. $0.18Stock buybacks: 66,469 sharesCASTLE ROCK, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) — Where Food Comes...

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at the American Society of Hematology (ASH) conference demonstrating meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor therapy use Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in Q4 2025, with data from both studies expected in 2H 2026 Strong financial position ending Q4 with approximately $791 million in cash, cash equivalents, and marketable securities,...

SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business HighlightsContinued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication. Further progress was made in the development of a new broadscale assay format including improvements designed to increase probe compatibility, performance, and...

– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. “As demonstrated in today’s release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron’s Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets,” said...

Fourth Quarter Revenue of $683 million, down 0.4% Year-over-Year; 2025 Revenue of $2,686 million, down 2% Year-over-Year Fourth Quarter Private Cloud Revenue of $241 million, down 10% Year-over-Year; 2025 Private Cloud Revenue of $990 million, down 6% Year-over-Year Fourth Quarter Public Cloud Revenue of $442 million, up 6% Year-over-Year; 2025 Public Cloud Revenue of $1,696 million up 1% Year-over-Year Fourth Quarter Cash Flow From Operating Activities of $60 million; 2025 Cash Flow From Operating Activities of $151 millionSAN ANTONIO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end hybrid cloud and AI solutions company, today announced results for its fourth quarter and year ended December 31, 2025. Gajen Kandiah, Chief Executive Officer, stated, “Q4 capped a year of meaningful...

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal net revenue growth of 23% to $92.9 million MACI® net revenue growth of 23% to $84.1 million Burn Care net revenue of $8.8 million Gross margin of 79% Net income increased 17% to $23.2 million Non-GAAP...